Drug Profile


Alternative Names: FUT-175; Futhan; Nafamostat mesilate; Nafamostat mesylate

Latest Information Update: 22 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Torii Pharmaceutical
  • Developer Banyu; Taiho Pharmaceutical; Torii Pharmaceutical
  • Class Anticoagulants; Guanidines; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Blood coagulation disorders; Disseminated intravascular coagulation; Pancreatitis
  • Discontinued Atherosclerosis; Autoimmune disorders; Cancer; Reperfusion injury; Xenotransplant rejection

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 May 1999 Preclinical development for Atherosclerosis in Japan (Unknown route)
  • 24 May 1999 Preclinical development for Coagulation disorders in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top